RIGL Q3 2017 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$503M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$900,000-76.1% YoY

Gross Profit

-$10M-1100.9% margin

Operating Income

-$18M-1983.9% margin

Net Income

-$18M-1962.2% margin

EPS (Diluted)

$-1.42

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$873,000

Balance Sheet

Total Assets

$71M

Total Liabilities

$15M

Stockholders' Equity

$56M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$900,000	$4M	-76.1%
Gross Profit	-$10M	-$12M	+20.2%
Operating Income	-$18M	-$23M	+21.5%
Net Income	-$18M	-$23M	+22.0%